47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 517
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 1,34M | 1,21M | 1976 |
Mr. Simon Nicolas Reade Harford | Chief Financial Officer | 531,99k | N/A | 1960 |
Ms. Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 832,06k | 287,61k | 1964 |
Mr. David M. Clark | Chief People Officer | 788,38k | N/A | 1976 |
Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer | 794,53k | N/A | 1972 |
Ms. Samantha Prout | Chief Accounting Officer & Controller | N/A | N/A | 1978 |
Dr. Jill Weimer Ph.D. | Chief Science Officer | N/A | N/A | N/A |
Andrew Faughnan | Senior Director of Investor Relations | N/A | N/A | N/A |
Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | N/A | N/A | N/A |
Ms. Diana Moore | Head of Global Corporate Communications | N/A | N/A | N/A |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 8, Vorstand: 3, Shareholderrechte: 7, Kompensation: 5.